Free Biopharma Daily Stock Updates - 06/22/21

$XBI $133.7 -.9%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$GLTO -2.7% Galecto’s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients. source

$SRNE +2.8% Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21. source

$TFFP -2.4% Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19. source

$OPK +1.6% BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry. source

Pipeline Updates

$KROS -1.6% Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes. source

$ENTA +0.3% Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients. source

$GMTX -4.5% Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. source

$HALO +2.1% Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma. source

$QURE -7.0% uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update. source

$ADCT -1.5% ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma. source

$CORT -4.4% Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. source

$VTVT +6.8% vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer. source

$DRNA -0.6% Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. source

$AGIO -7.2% Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency. source

$LCTX +2.1% Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing. source

$HALO +2.1% ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV. source

$TBIO +10.3% Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine. source

$SAVA -13.5% On 6/21 Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease. source

$RXDX -14.1% On 6/21 Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform. source

$ATOS +19.2% On 6/16 Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes. source

Financial Updates

$BTAI -3.6% BioXcel Therapeutics Announces Proposed Public Offering of Common Stock. source

$QURE -7.0% uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE). source

$ABCL -2.9% AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada. source

$PCRX 0.3% Pacira Announces EXPAREL Distribution Agreement with Eurofarma in Latin America. source

$NTLA -0.4% Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company. source

$IDRA +41.1% Idera Pharmaceuticals up 22% following insider share purchase. source

---

Posted by FS